Archive for the ‘Health Policy’ Category

A Replay of the Golden Oldies in Obesity Policy

September 13, 2024 — In a perverse way, it is nostalgic. Yesterday, the Trust for America’s Health (TFAH) published the latest edition of their annual series: State of Obesity 2024. Though the subtitle is “Better Policies for a Healthier America,” it seems more like a replay of golden oldies in obesity policy. Reading this report, we come away with […]

Losing Patience with Drug Labels Dismissing People with Obesity

September 9, 2024 — The American College of Clinical Pharmacology is meeting in Bethesda this week. On the opening day, ACCP convened a symposium to address critical questions about how drugs work in people with obesity. What can we – industry, FDA, and scientists – do better? Because all too often, drug labels to guide safe prescribing are effectively […]

Accounting for the Harm of Menu Labeling with Minimal Benefits

September 8, 2024 — What’s the harm? For many “interventions” to reduce obesity prevalence, this rationale seems to be good enough to spur implementation. Menu labeling is a good example. Restaurants in the U.S. and in numerous other places must publish the number of calories in food portions they sell. This went into effect based upon suppositions. Policy makers […]

The Gap in Patient Assistance for Obesity Medicines

September 7, 2024 — Recently, Novo Nordisk CEO Lars Fruergaard Jørgensen did a rare interview with NBC News to talk about the high price of obesity medicines that are proving to be so important for so many people. It seemed like a dress rehearsal for his coming appearance at a Senate hearing on the subject. He brought up the […]

Obesity Care at Scale Will Profoundly Change Health Systems

September 6, 2024 — Think about it. Profound change is coming to healthcare and health systems because of the imperative for obesity care at scale. Right now, we are seeing only a faint glimmer of the changes that lie ahead. That’s because the biggest struggles with this change are very basic. Lilly and Novo Nordisk are straining to produce […]

ESC Congress: Everyone Now Claims the Disease of Obesity

September 4, 2024 — If nothing else, the ESC (European for Cardiology) Congress in London this week made one thing clear – everyone in mainstream medicine is now ready to claim the disease of obesity. Cardiologists all over the world are adopting a view we’ve been espousing here for decades. Obesity is not a lifestyle. Not a behavioral problem. […]

Polluting the Food Supply with PFAS

September 3, 2024 — For decades, the Environmental Protection Agency has promoted the use of sludge from sewage treatment plants as fertilizer. It seemed like a good idea at the time. The sludge – known as biosolids in the fertilizer industry – is rich in nutrients that crops need. Plus, using biosolids for this purpose kept them out of […]

Rational and Irrational Exuberance About GLP-1 Medicines

September 2, 2024 — It’s true. We have been getting some pretty good news about GLP-1s lately. In persons with prediabetes and obesity, tirzepatide was 94% effective at preventing the development of diabetes. In the SELECT study, semaglutide for obesity might have cut COVID fatalities by a third. So a little exuberance about the potential of GLP-1 medicines is […]

A Simple and Cost-Effective Way to Reduce Type 2 Diabetes?

August 28, 2024 — Type 2 diabetes prevalence is up and the Lancet Regional Health has a simple way to reduce it. Daniel Windred and colleagues write: “Advising people to turn off their lights at night, or use lights that reduce the circadian impact (dim and “warm” light), is a simple, cost-effective, and easily-implementable recommendation that may promote cardiometabolic […]

A Quick 50% Price Cut for Low-Dose Zepbound (tirzepatide)

August 27, 2024 — That was quick. At about 6 am today, we posted to say that obesity drug prices are stuck in the spotlight. “Bold leadership on obesity drug pricing and access to care is the only thing that will bring relief from this uncomfortable spotlight,” we wrote. Before the end of the hour, Lilly took the cue. […]